Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Liver Diseases

  Free Subscription

Articles published in J Gastroenterol

Retrieve available abstracts of 109 articles:
HTML format

Single Articles

    July 2021
  1. LI D, Ding X, Tian D, Xia L, et al
    Reply to: "COVID-19-associated liver injury (COVALI): role of hepatologists".
    J Gastroenterol. 2021 Jul 12. pii: 10.1007/s00535-021-01807.

  2. YOSHIJI H, Nagoshi S, Akahane T, Asaoka Y, et al
    Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    J Gastroenterol. 2021 Jul 7. pii: 10.1007/s00535-021-01788.
    PubMed     Abstract available

  3. SUMIDA Y, Yoneda M
    COVID-19-associated liver injury (COVALI): role of hepatologists.
    J Gastroenterol. 2021 Jul 2. pii: 10.1007/s00535-021-01809.

    May 2021
  4. OKUSAKA T, Ikeda K, Kudo M, Finn R, et al
    Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    J Gastroenterol. 2021 May 4. pii: 10.1007/s00535-021-01785.
    PubMed     Abstract available

    March 2021
  5. MAK LY, Huang Q, Wong DK, Stamm L, et al
    Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy.
    J Gastroenterol. 2021 Mar 27. pii: 10.1007/s00535-021-01780.
    PubMed     Abstract available

  6. NAKATSUKA T, Nakagawa H, Hayata Y, Wake T, et al
    Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
    J Gastroenterol. 2021 Mar 12. pii: 10.1007/s00535-021-01773.
    PubMed     Abstract available

  7. HUO TI, Ho SY, Liu PH
    Changing patterns of etiology and management of hepatocellular carcinoma: need for global reappraisal.
    J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01770.

  8. ENOMOTO H, Nishiguchi S
    Reply to the letter by Huo et al. regarding our manuscript "The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan".
    J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01768.

  9. LI D, Ding X, Xie M, Tian D, et al
    COVID-19-associated liver injury: from bedside to bench.
    J Gastroenterol. 2021;56:218-230.
    PubMed     Abstract available

    February 2021
  10. ISHIKAWA T, Sasaki R, Nishimura T, Matsuda T, et al
    Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism.
    J Gastroenterol. 2021 Feb 24. pii: 10.1007/s00535-021-01762.
    PubMed     Abstract available

    January 2021
  11. TERAI S, Buchanan-Hughes A, Ng A, Lee IH, et al
    Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
    J Gastroenterol. 2021 Jan 26. pii: 10.1007/s00535-021-01759.
    PubMed     Abstract available

  12. TATEISHI R, Matsumura T, Okanoue T, Shima T, et al
    Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.
    J Gastroenterol. 2021 Jan 11. pii: 10.1007/s00535-020-01754.
    PubMed     Abstract available

  13. KUDO M, Tsuchiya K, Kato N, Hagihara A, et al
    Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.
    J Gastroenterol. 2021 Jan 3. pii: 10.1007/s00535-020-01753.
    PubMed     Abstract available

  14. HARADA M
    Diagnosis for Wilson disease: this disease may not be a rare disease.
    J Gastroenterol. 2021;56:114-115.

    December 2020
  15. OCHI H, Hiraoka A, Hirooka M, Koizumi Y, et al
    Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
    J Gastroenterol. 2020 Dec 5. pii: 10.1007/s00535-020-01747.
    PubMed     Abstract available

    November 2020
  16. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.
    J Gastroenterol. 2020 Nov 20. pii: 10.1007/s00535-020-01748.
    PubMed     Abstract available

  17. SUZUKI K, Suda G, Yamamoto Y, Furuya K, et al
    Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
    J Gastroenterol. 2020 Nov 19. pii: 10.1007/s00535-020-01750.
    PubMed     Abstract available

    October 2020
  18. YU WL, Yu G, Dong H, Chen K, et al
    Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2020 Oct 21. pii: 10.1007/s00535-020-01729.
    PubMed     Abstract available

  19. MIKI D, Akita T, Kurisu A, Kawaoka T, et al
    PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
    J Gastroenterol. 2020 Oct 15. pii: 10.1007/s00535-020-01731.
    PubMed     Abstract available

  20. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    PubMed     Abstract available

    September 2020
  21. YIP TC, Lai JC, Wong GL
    Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
    J Gastroenterol. 2020 Sep 24. pii: 10.1007/s00535-020-01726.
    PubMed     Abstract available

  22. HIRAMINE Y, Uto H, Mawatari S, Kanmura S, et al
    Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    J Gastroenterol. 2020 Sep 21. pii: 10.1007/s00535-020-01727.
    PubMed     Abstract available

    August 2020
  23. UCHIDA Y, Uemura H, Yamaba S, Hamada D, et al
    Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19.
    J Gastroenterol. 2020 Aug 9. pii: 10.1007/s00535-020-01717.
    PubMed     Abstract available

  24. MARASCO G, Serenari M, Renzulli M, Alemanni LV, et al
    Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments.
    J Gastroenterol. 2020 Aug 3. pii: 10.1007/s00535-020-01711.
    PubMed     Abstract available

    July 2020
  25. TANAKA H, Okamoto K, Sato Y, Tanaka T, et al
    Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.
    J Gastroenterol. 2020 Jul 14. pii: 10.1007/s00535-020-01705.
    PubMed     Abstract available

    June 2020
  26. LIANG LY, Wong VW, Toyoda H, Tse YK, et al
    Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.
    J Gastroenterol. 2020 Jun 17. pii: 10.1007/s00535-020-01700.
    PubMed     Abstract available

  27. SAWADA Y, Shiraki M, Iwasa M, Hiraoka A, et al
    The effects of diuretic use and the presence of ascites on muscle cramps in patients with cirrhosis: a nationwide study.
    J Gastroenterol. 2020 Jun 12. pii: 10.1007/s00535-020-01694.
    PubMed     Abstract available

    May 2020
  28. SAKAIDA I, Terai S, Kurosaki M, Okada M, et al
    Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    J Gastroenterol. 2020 May 9. pii: 10.1007/s00535-020-01691.
    PubMed     Abstract available

    March 2020
  29. KAWAGUCHI T, Torimura T
    Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?
    J Gastroenterol. 2020;55:363-364.

    February 2020
  30. KUDO M, Okusaka T, Motomura K, Ohno I, et al
    Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
    J Gastroenterol. 2020 Feb 27. pii: 10.1007/s00535-020-01668.
    PubMed     Abstract available

  31. TAKEHARA T, Chayama K, Kurosaki M, Yatsuhashi H, et al
    JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.
    J Gastroenterol. 2020 Feb 17. pii: 10.1007/s00535-020-01672.
    PubMed     Abstract available

    January 2020
  32. KAJI K, Yoshiji H
    Can portal hypertension and hepatic decompensation be predicted?
    J Gastroenterol. 2020 Jan 21. pii: 10.1007/s00535-020-01669.

    December 2019
  33. SCHWARZER R, Reiberger T, Mandorfer M, Kivaranovic D, et al
    The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.
    J Gastroenterol. 2019 Dec 12. pii: 10.1007/s00535-019-01656.
    PubMed     Abstract available

    November 2019
  34. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    Transition in the etiology of liver cirrhosis in Japan: a nationwide survey.
    J Gastroenterol. 2019 Nov 25. pii: 10.1007/s00535-019-01645.
    PubMed     Abstract available

  35. YAMASHITA T, Kudo M, Ikeda K, Izumi N, et al
    REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
    J Gastroenterol. 2019 Nov 12. pii: 10.1007/s00535-019-01642.
    PubMed     Abstract available

    October 2019
  36. ENOOKU K, Tsutsumi T, Kondo M, Fujiwara N, et al
    Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
    J Gastroenterol. 2019 Oct 10. pii: 10.1007/s00535-019-01633.
    PubMed     Abstract available

    September 2019
  37. KIM D, Kim W, Joo SK, Han J, et al
    Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis.
    J Gastroenterol. 2019 Sep 18. pii: 10.1007/s00535-019-01628.
    PubMed     Abstract available

  38. ESO Y, Shimizu T, Takeda H, Takai A, et al
    Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
    J Gastroenterol. 2019 Sep 7. pii: 10.1007/s00535-019-01620.
    PubMed     Abstract available

  39. PUIGVEHI M, Londono MC, Torras X, Lorente S, et al
    Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients.
    J Gastroenterol. 2019 Sep 6. pii: 10.1007/s00535-019-01619.
    PubMed     Abstract available

  40. NAMBA M, Hiramatsu A, Aikata H, Kodama K, et al
    Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    J Gastroenterol. 2019 Sep 4. pii: 10.1007/s00535-019-01623.
    PubMed     Abstract available

    August 2019
  41. TATEISHI R, Koike K
    Changing etiology of hepatocellular carcinoma.
    J Gastroenterol. 2019 Aug 31. pii: 10.1007/s00535-019-01622.

  42. HUO TI, Ho SY
    Evolution of hepatocellular carcinoma: non-B, non-C and beyond.
    J Gastroenterol. 2019 Aug 30. pii: 10.1007/s00535-019-01621.

  43. EBADI M, Bhanji RA, Mazurak VC, Montano-Loza AJ, et al
    Sarcopenia in cirrhosis: from pathogenesis to interventions.
    J Gastroenterol. 2019 Aug 7. pii: 10.1007/s00535-019-01605.
    PubMed     Abstract available

    July 2019
  44. SHIMADA S, Tanaka S
    A new era for understanding genetic evolution of multistep carcinogenesis.
    J Gastroenterol. 2019;54:667-668.
    PubMed     Abstract available

    June 2019
  45. MIZUNO K, Toyoda H, Yasuda S, Tada T, et al
    The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.
    J Gastroenterol. 2019 Jun 3. pii: 10.1007/s00535-019-01595.
    PubMed     Abstract available

    May 2019
  46. NAGANUMA M, Sugimoto S, Suzuki H, Matsuno Y, et al
    Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey.
    J Gastroenterol. 2019 May 17. pii: 10.1007/s00535-019-01591.
    PubMed     Abstract available

    April 2019
  47. MANO Y, Yoshio S, Shoji H, Tomonari S, et al
    Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.
    J Gastroenterol. 2019 Apr 2. pii: 10.1007/s00535-019-01579.
    PubMed     Abstract available

    March 2019
  48. SUMIDA Y, Yoneda M, Okanoue T
    Is the grade of ballooned hepatocytes a significant risk factor for rapid progression of hepatic fibrosis in patients with NAFLD?
    J Gastroenterol. 2019 Mar 26. pii: 10.1007/s00535-019-01573.

  49. KAKISAKA K, Suzuki Y, Fujiwara Y, Abe T, et al
    Response to the letter by Sumida et al. regarding our manuscript "Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease".
    J Gastroenterol. 2019 Mar 26. pii: 10.1007/s00535-019-01574.

  50. NAGANUMA A, Chayama K, Notsumata K, Gane E, et al
    Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    J Gastroenterol. 2019 Mar 13. pii: 10.1007/s00535-019-01569.
    PubMed     Abstract available

  51. KADO A, Tsutsumi T, Enooku K, Fujinaga H, et al
    Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.
    J Gastroenterol. 2019 Mar 4. pii: 10.1007/s00535-019-01565.
    PubMed     Abstract available

  52. SEKO Y
    Reply to: Sarcopenia definition in patients with NAFLD.
    J Gastroenterol. 2019;54:298.

  53. PENG TC
    Sarcopenia definition in patients with NAFLD.
    J Gastroenterol. 2019;54:297.

    February 2019
  54. TSUSHIMA K, Tsuge M, Hiraga N, Uchida T, et al
    Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice.
    J Gastroenterol. 2019 Feb 21. pii: 10.1007/s00535-019-01558.
    PubMed     Abstract available

  55. KOBAYASHI M, Kudo M, Izumi N, Kaneko S, et al
    Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
    J Gastroenterol. 2019 Feb 20. pii: 10.1007/s00535-019-01554.
    PubMed     Abstract available

  56. KIM SK, Takeda H, Takai A, Matsumoto T, et al
    Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis.
    J Gastroenterol. 2019 Feb 12. pii: 10.1007/s00535-019-01555.
    PubMed     Abstract available

  57. KANNO M, Kawaguchi K, Honda M, Horii R, et al
    Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
    J Gastroenterol. 2019 Feb 1. pii: 10.1007/s00535-019-01551.
    PubMed     Abstract available

  58. SHIRABE K, Bekki Y, Gantumur D, Araki K, et al
    Response to the letter by Dr. Naoya Yamada, and Dr. Koichi Mizuta regarding our manuscript: "Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis".
    J Gastroenterol. 2019;54:206-207.

  59. TATEISHI R, Seike M, Kudo M, Tamai H, et al
    A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
    J Gastroenterol. 2019;54:171-181.
    PubMed     Abstract available

  60. MIZUNO N, Seko Y, Kataoka S, Okuda K, et al
    Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease.
    J Gastroenterol. 2019;54:160-170.
    PubMed     Abstract available

    January 2019
  61. BRAR G, Tsukamoto H
    Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science.
    J Gastroenterol. 2019 Jan 14. pii: 10.1007/s00535-018-01542.
    PubMed     Abstract available

  62. KIMURA K
    Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
    J Gastroenterol. 2019 Jan 1. pii: 10.1007/s00535-018-01538.

    November 2018
  63. RAKSAYOT M, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, et al
    Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.
    J Gastroenterol. 2018 Nov 30. pii: 10.1007/s00535-018-01533.
    PubMed     Abstract available

  64. TATEISHI R, Uchino K, Fujiwara N, Takehara T, et al
    A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.
    J Gastroenterol. 2018 Nov 29. pii: 10.1007/s00535-018-1532.
    PubMed     Abstract available

  65. YAMADA N, Mizuta K
    Advanced assessment of serum Mac-2 binding protein glycosylation isomer in patients with biliary atresia.
    J Gastroenterol. 2018 Nov 9. pii: 10.1007/s00535-018-1523.

    October 2018
  66. IIO E, Matsuura K, Shimada N, Atsukawa M, et al
    TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.
    J Gastroenterol. 2018 Oct 31. pii: 10.1007/s00535-018-1526.
    PubMed     Abstract available

  67. PARK HE, Lee H, Choi SY, Kwak MS, et al
    Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter.
    J Gastroenterol. 2018 Oct 4. pii: 10.1007/s00535-018-1516.
    PubMed     Abstract available

    September 2018
  68. TAKEHARA T, Sakamoto N, Nishiguchi S, Ikeda F, et al
    Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    J Gastroenterol. 2018 Sep 10. pii: 10.1007/s00535-018-1503.
    PubMed     Abstract available

    July 2018
  69. SHIMA T, Uto H, Ueki K, Kohgo Y, et al
    Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients.
    J Gastroenterol. 2018 Jul 13. pii: 10.1007/s00535-018-1494.
    PubMed     Abstract available

    June 2018
  70. HUANG R, Wang J, Xia J, Hao Y, et al
    Potential clinical application of strain elastography in chronic liver diseases.
    J Gastroenterol. 2018;53:795-796.

  71. TAJIRI K, Kawai K, Sugiyama T
    Reply to "Letter to Editor submitted by Rui Huang et al. entitled potential clinical application of strain elastography in chronic liver diseases".
    J Gastroenterol. 2018;53:797-798.

    May 2018
  72. ENOOKU K, Kondo M, Fujiwara N, Sasako T, et al
    Hepatic IRS1 and ss-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients.
    J Gastroenterol. 2018 May 10. pii: 10.1007/s00535-018-1472.
    PubMed     Abstract available

  73. ORIMO T, Kamiyama T, Mitsuhashi T, Kamachi H, et al
    Impact of tumor localization on the outcomes of surgery for an intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2018 May 2. pii: 10.1007/s00535-018-1469.
    PubMed     Abstract available

    April 2018
  74. KAKISAKA K, Suzuki Y, Fujiwara Y, Abe T, et al
    Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    J Gastroenterol. 2018 Apr 21. pii: 10.1007/s00535-018-1468.
    PubMed     Abstract available

  75. YAGI M, Tanaka A, Namisaki T, Takahashi A, et al
    Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
    J Gastroenterol. 2018 Apr 16. pii: 10.1007/s00535-018-1465.
    PubMed     Abstract available

    February 2018
  76. YONEDA M, Imajo K, Takahashi H, Ogawa Y, et al
    Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.
    J Gastroenterol. 2018;53:181-196.
    PubMed     Abstract available

  77. NAKAHARA T, Hyogo H, Ono A, Nagaoki Y, et al
    Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.
    J Gastroenterol. 2018;53:269-280.
    PubMed     Abstract available

    December 2017
  78. SHINKAI N, Nojima M, Iio E, Matsunami K, et al
    High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
    J Gastroenterol. 2017 Dec 29. pii: 10.1007/s00535-017-1424.
    PubMed     Abstract available

  79. VITALE G, Gitto S, Raimondi F, Mattiaccio A, et al
    Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing.
    J Gastroenterol. 2017 Dec 13. pii: 10.1007/s00535-017-1423.
    PubMed     Abstract available

    November 2017
  80. SUZUKI Y, Mori T, Yokoyama M, Kim S, et al
    A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort.
    J Gastroenterol. 2017 Nov 8. doi: 10.1007/s00535-017-1410.
    PubMed     Abstract available

  81. SHANG L, Hosseini M, Liu X, Kisseleva T, et al
    Human hepatic stellate cell isolation and characterization.
    J Gastroenterol. 2017 Nov 1. doi: 10.1007/s00535-017-1404.
    PubMed     Abstract available

    October 2017
  82. KOYAMA N, Yamazaki T, Kanetsuki Y, Hirota J, et al
    Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 30. doi: 10.1007/s00535-017-1398.
    PubMed     Abstract available

  83. NAKAO M, Nakayama N, Uchida Y, Tomiya T, et al
    Nationwide survey for acute liver failure and late-onset hepatic failure in Japan.
    J Gastroenterol. 2017 Oct 13. doi: 10.1007/s00535-017-1394.
    PubMed     Abstract available

  84. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Erratum to: Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 11. doi: 10.1007/s00535-017-1392.
    PubMed     Abstract available

    September 2017
  85. CHAYAMA K, Suzuki F, Karino Y, Kawakami Y, et al
    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391.
    PubMed     Abstract available

  86. IMPERATORE N, Tortora R, Testa A, Gerbino N, et al
    Erratum to: Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet.
    J Gastroenterol. 2017 Sep 19. doi: 10.1007/s00535-017-1393.
    PubMed     Abstract available

    August 2017
  87. KAWAGUCHI K, Honda M, Ohta H, Terashima T, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    J Gastroenterol. 2017 Aug 28. doi: 10.1007/s00535-017-1386.
    PubMed     Abstract available

  88. IMPERATORE N, Tortora R, Anna T, Gerbino N, et al
    Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet.
    J Gastroenterol. 2017 Aug 19. doi: 10.1007/s00535-017-1381.
    PubMed     Abstract available

  89. KOBAYASHI K, Maruyama H, Kiyono S, Ogasawara S, et al
    Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis.
    J Gastroenterol. 2017 Aug 18. doi: 10.1007/s00535-017-1378.
    PubMed     Abstract available

  90. SHIDA T, Akiyama K, Oh S, Sawai A, et al
    Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease.
    J Gastroenterol. 2017 Aug 8. doi: 10.1007/s00535-017-1377.
    PubMed     Abstract available

  91. IKEDA M, Kudo M, Aikata H, Nagamatsu H, et al
    Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
    J Gastroenterol. 2017 Aug 1. doi: 10.1007/s00535-017-1374.
    PubMed     Abstract available

    July 2017
  92. KITAJIMA Y, Takahashi H, Akiyama T, Murayama K, et al
    Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis.
    J Gastroenterol. 2017 Jul 24. doi: 10.1007/s00535-017-1370.
    PubMed     Abstract available

  93. SEKO Y, Sumida Y, Sasaki K, Itoh Y, et al
    Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
    J Gastroenterol. 2017 Jul 1. doi: 10.1007/s00535-017-1364.
    PubMed     Abstract available

    June 2017
  94. HIRAMINE Y, Uojima H, Nakanishi H, Hiramatsu A, et al
    Response criteria of tolvaptan for the treatment of hepatic edema.
    J Gastroenterol. 2017 Jun 29. doi: 10.1007/s00535-017-1366.
    PubMed     Abstract available

  95. OKANOUE T, Ebise H, Kai T, Mizuno M, et al
    A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    J Gastroenterol. 2017 Jun 6. doi: 10.1007/s00535-017-1355.
    PubMed     Abstract available

  96. TAJIRI K, Kawai K, Sugiyama T
    Strain elastography for assessment of liver fibrosis and prognosis in patients with chronic liver diseases.
    J Gastroenterol. 2017;52:724-733.
    PubMed     Abstract available

    May 2017
  97. MASUDA K, Ono A, Aikata H, Kawaoka T, et al
    Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    J Gastroenterol. 2017 May 29. doi: 10.1007/s00535-017-1352.

  98. OBA A, Kudo A, Akahoshi K, Kishino M, et al
    A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors.
    J Gastroenterol. 2017 May 9. doi: 10.1007/s00535-017-1349.
    PubMed     Abstract available

  99. MASUDA K, Ono A, Aikata H, Kawaoka T, et al
    Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    J Gastroenterol. 2017 May 4. doi: 10.1007/s00535-017-1348.
    PubMed     Abstract available

    April 2017
  100. KIM TJ, Sinn DH, Min YW, Son HJ, et al
    A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease.
    J Gastroenterol. 2017 Apr 5. doi: 10.1007/s00535-017-1337.
    PubMed     Abstract available

  101. FLOREANI A, Tanaka A, Bowlus C, Gershwin ME, et al
    Geoepidemiology and changing mortality in primary biliary cholangitis.
    J Gastroenterol. 2017 Apr 1. doi: 10.1007/s00535-017-1333.
    PubMed     Abstract available

    March 2017
  102. CAI X, Hayashi S, Fang C, Hao S, et al
    Pu'erh tea extract-mediated protection against hepatosteatosis and insulin resistance in mice with diet-induced obesity is associated with the induction of de novo lipogenesis in visceral adipose tissue.
    J Gastroenterol. 2017 Mar 31. doi: 10.1007/s00535-017-1332.
    PubMed     Abstract available

  103. ZHANG AY, Lai CL, Huang FY, Seto WK, et al
    Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma.
    J Gastroenterol. 2017 Mar 28. doi: 10.1007/s00535-017-1334.
    PubMed     Abstract available

  104. KISHIDA Y, Okubo H, Ohno H, Oki K, et al
    Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
    J Gastroenterol. 2017 Mar 27. doi: 10.1007/s00535-017-1331.
    PubMed     Abstract available

  105. HASEBE T, Tanaka H, Sawada K, Nakajima S, et al
    Bone morphogenetic protein-binding endothelial regulator of liver sinusoidal endothelial cells induces iron overload in a fatty liver mouse model.
    J Gastroenterol. 2017;52:341-351.
    PubMed     Abstract available

    February 2017
  106. SETO WK, Yuen MF
    Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    J Gastroenterol. 2017;52:164-174.
    PubMed     Abstract available

  107. MORIO R, Hyogo H, Hatooka M, Morio K, et al
    The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.
    J Gastroenterol. 2017;52:253-262.
    PubMed     Abstract available

  108. MIYAKE T, Hirooka M, Yoshida O, Furukawa S, et al
    Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels.
    J Gastroenterol. 2017;52:237-244.
    PubMed     Abstract available

    June 2016
  109. YAMADA N, Sanada Y, Tashiro M, Hirata Y, et al
    Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia.
    J Gastroenterol. 2016.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.